Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 +13.77%50 Equity-to-Asset is 0.56 as of Dec. 2025, which is 8% above its 10-year median of 0.52. GuruFocus rates FRA:VB0 with a GF Score™ of 50/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Viva Biotech Holdings ranks worse than 62.28% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Viva Biotech Holdings Equity-to-Asset Related Terms
Viva Biotech Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Viva Biotech Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VB0 vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Viva Biotech Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Viva Biotech Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a Equity-to-Asset of 0.56 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viva Biotech Holdings and its competitors. This is near median its historical median of 0.52. Over the past decade, Viva Biotech Holdings' Equity-to-Asset has ranged from 0.46 to 0.94. According to the industry distribution chart, Viva Biotech Holdings ranks #880 out of 1413 companies in the Biotechnology industry, placing it in the top 62.3%.
Is Viva Biotech Holdings' Equity-to-Asset too high?
Viva Biotech Holdings' current Equity-to-Asset of 0.56 is near median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.68. Viva Biotech Holdings' value of 0.56 is 17.6% below this industry median. Based on the distribution chart, Viva Biotech Holdings ranks #880 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viva Biotech Holdings has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #880 out of 1413 companies for Equity-to-Asset. This places Viva Biotech Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Viva Biotech Holdings' value of 0.56 is 17.6% below this benchmark. Historically, Viva Biotech Holdings' own Equity-to-Asset has ranged from 0.46 to 0.94 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.68, Viva Biotech Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viva Biotech Holdings's current Equity-to-Asset of 0.56 is 17.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Viva Biotech Holdings and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viva Biotech Holdings's current Equity-to-Asset is 0.56, which is near median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.16 — trading 96.3% above its estimated fair value. The current Equity-to-Asset is 0.56, which is near median its 10-year median of 0.52 and 17.6% below the Biotechnology industry median of 0.68. Viva Biotech Holdings' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current Equity-to-Asset is 0.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.16 is trading 96.3% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
Equity-to-Asset: 0.56 (near median its 10-year median of 0.52)
GF Value™: €0.08 vs. price of €0.16 (96.3% above fair value)
Industry Position: 17.6% below the Biotechnology median (#880 of 1413)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
50GF Score
Get the complete analysis for FRA:VB0
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
